Conduct↦Management↦Responsibility and Oversight↦Drug and Device Accountability
Was betrifft es? Warum ist das wichtig?
Drug and Device Accountability (DDA) refers to the study documentation of an Investigational Therpeutic Product (IP), such as an IMP or IMD (e.g. shipment, storage, preparation, use, destruction).
For a SP-INV, DDA accountability:
- Starts with ordering IPs from a manufacturer:
- Continues with the distribution to participating study sites
- Ends with IP destruction, which may also be the end of a required archiving period
For a Site-INV, DDA accountability:
- Starts once the IP is delivered to the study site
- Continues with ongoing IP tracking during study conduct. Such as the IP being:
- Removed from storage site, or delivered by a hospital pharmacy
- Distributed to study participants
- Returned by participants to the study site
- Ends with used or un-used IP being returned to the SP-INV or destroyed at the study site
DDA-logs are subject to reviews during study monitoring visits, and potential RA inspections (e.g. Swissmedic).
Mehr
IP oversight also includes a:
- Collaboration with IP providers (e.g. MAH, pharmacy)
- SP-INV specifications regarding IP storage requirements (e.g. required storage temperature, humidity, light), including faultless IP storage, based on IP instruction for use
- Restricted access to IP-storage sites (e.g. study site delegation-log). This ensures that the DDA-log remains current and correct, and IP is protected against accidental loss or damage
- Faultless IP dispensing to study participants (e.g. IP preparation, IP labelling information, IP dosage escalations, removal of damaged IP, faultless execution)
- Faultless ongoing IP documentation. This includes the proof that any placebo or comparator was handled and administered according to the study protocol
Was muss ich befolgen?
As a SP-INV, implement DDA procedures and document IP:
- Ordered and received by licensed providers (e.g. pharmacy, manufacturer)
- Distributed to study sites
- Used during study conduct (e.g. based on the monitoring of IP-use by study participants – used/not used)
- Expiration and any stability testing during study conduct
- Returned from participating study sites, including its destruction
As a Site-INV, maintain ongoing oversight of IP-Inventory and use. Document ongoing:
- IP delivered to the study site (e.g. on behalf of the SP-INV)
- IP handed out and returned by study participants (e.g. IP-Accountability-Log and IP-Destruction-Log)
As a Site-INV, manage IP storage, such as to:
- Ensure ongoing optimal storage conditions
- Check for expired IPs and if applicable:
- Send expired IPs for stability testing
- Relabel IPs (i.e. based on SP-INV SOPs) with the SP-INV approved updated expiration date
- Return unused or expired IPs to the SP-INV, or destroy IPs based on SP-INV SOPs
Mehr
As a Site-INV, during study conduct:
- Do not discard empty IP blisters, vials, or bottles before the study monitor was able to document its use. This information enables the SP-INV to track IP-use at the study site during study conduct (e.g. use is tracked based on which study participant received and used which IP lot/serial number)
- In the event IPs are destroyed at the study site, provide the SP-INV with a certificate of destruction
Wo kann ich Hilfe anfordern?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular guidelines
- 2.10 Investigational Product Management (Investigator)
- 3.15 Investigational Product(s)
- 3.15.3 Supplying and handling investigational products(s)
- C.3 Essentiality of Trial Records - Accountability
ISO 14155:2020 Medical devices (access liable to cost) - see in particular section
- 7.9 Investigational device accountability